Table 3.

A list of immunotherapy based clinical trials for neuroblastoma

Columnl	Column2	Column3	Column4
Trials identifier No.	Trial status	Drug/agent used	NB patient feature
NCT02169609	Active, not recruiting	Dinutuximab (Ch 14.18) GM-CSF and IL-2	high-risk neuroblastoma
NCT02573896	Yet to recruit	ch14.18/Lenalidomide	relapsed refractory neuroblastoma
NCT01183897	Active, not recruiting	Hu3F8/GM-CSF and 13-Cis-Retinoic Acid	primary refractory neuroblastoma in bone marrow
NCT03033303	Recruiting	Hu3F8/GM-CSF Isotretinoin	high-risk neuroblastoma with first remission
NCT01183884	Active, not recruiting	3F8/GM-CSF 13-Cis-Retinoic Acid	high-risk neuroblastoma with second or greater remission
NCT01183429	Active, not recruiting	3F8/GM-CSF 13-Cis-Retinoic Acid	non-myeloablative therapy with high-risk neuroblastoma in first remission
NCT02765243	Recruiting	4SCAR-GD2 T cells	refractory or recurrent neuroblastoma
NCT02311621	Recruiting	genetically modified T cells to express CAR	recurrent or refractory neuroblastoma
NCT01183416	Active, not recruiting	High-dose 3F8/GM-CSF and 13-cis-retinoic acid	autologous stem-cell transplantation after myeloablative therapy first remission
NCT03242603	Recruiting	Anti-GD2/ NK Cells	high-risk neuroblastoma
NCT02130869	Recruiting	CD133+ selected autologous stem cell infusion/hu 14.18K322A	high-risk neuroblastoma
NCT02919046	Recruiting	GD2-targeted CAR-T cells	Relapsed or refractory neuroblastoma
NCT02173093	Recruiting	GD2 bispecific antibody	Children with neuroblastoma and osteosarcoma

Abbreviations: GM-CSF: granulocyte-macrophage colony stimulating factor, NK: natural killer cells, GD2: disialoganglioside, Hu3F8: humanized 3F8 monoclonal antibody; CAR: chimeric antigen receptor